Latest Beverages News

Bega Cheese Limited has delivered a robust FY2026 with a $54.8 million statutory profit, a 6.7% revenue increase, and a raised final dividend of 7.5 cents per share. The company is advancing its strategic growth plans focused on high-protein products, international expansion, and sustainability initiatives.

Auckland Airport posted a 3% revenue increase and a stable underlying profit of NZD 309 million in FY26, driven by robust passenger growth and a $1 billion infrastructure push, while cautioning on near-term fuel price volatility and geopolitical risks.

Orora’s FY26 results reveal a $616.6 million statutory loss driven by a $742.8 million Glass impairment, offset by robust growth in its Cans business and disciplined capital management.

De.mem Limited is poised for a record 2026, driven by 29 consecutive quarters of cash receipts growth, positive operating cashflow, and strategic expansion into the gold mining sector through Core Chemicals.

Argent BioPharma's licensing partner Splash Beverage Group has launched the US veterinary development program for CannEpil®, targeting companion-animal oncology and chronic pain. Led by industry veteran Dr Hunter Land, the initiative follows a defined FDA regulatory pathway and could broaden CannEpil®’s commercial footprint beyond human neurology.

AoFrio’s revenue fell 21.5% in 1H26, dragged down by a 50.5% plunge in motor sales due to US tariffs, while IoT revenue grew modestly. The company launched new cellular and software platforms, raised NZD 8.9 million, and is expanding into Food Retail, but full-year revenue growth now looks unlikely.

Peak Processing (ASX: PKP) has recorded its first positive Group EBITDA quarter, driven by record beverage production and a significant US manufacturing agreement, marking a pivotal turnaround in FY26.

De.mem Limited posted its second highest quarterly cash receipts of approximately $9.6 million for June 2026, marking 29 consecutive quarters of growth and positive operating cash flow of $424k. The company’s strong half-year performance is underpinned by recurring revenues, a robust Western Australian business, and record results from its German subsidiary.

Argent BioPharma has eliminated US$5.5 million in secured debt through a global licensing agreement for its CannEpil® epilepsy therapy, while completing a key acquisition and advancing clinical trials in veterinary therapeutics.

Barramundi’s portfolio returned a solid 3.8% gross gain in Q2 2026, driven by strong AI-related infrastructure plays and takeover interest in key holdings, despite sector volatility and profit downgrades in healthcare and logistics.

SPC Global reported solid Q4 FY26 growth driven by domestic beverage sales and a 50.8% jump in international revenue, while a $100 million equity raise slashed net leverage and paved the way for improved cash flow in FY27.

Argent BioPharma has struck a global licensing deal for its CannEpil® epilepsy therapy with Splash Beverage Group, securing US$5.5 million upfront through convertible debt forgiveness and retaining manufacturing and intellectual property rights alongside a 15% royalty on future sales.